Just a few short weeks removed from barely surviving a call to be removed from the marketplace, GlaxoSmithKline’s diabetes drug Avandia has been linked to an increased risk of bone fractures in postmenopausal women. Actos, Avandia’s chief rival, was also linked to the increased risk of bone fractures.
Both Avandia and Actos belong to the same class of drugs known as thiazolidinediones.
The study’s findings were published in the Journal of Clinical Endocrinology & Metabolism. It found that women over 50 who were prescribed these types of drugs were 71% more likely to have suffered a bone fracture.
While Avandia has been allowed to remain on the market its sales have declined sharply due to the numerous calls for its removal from the marketplace due to safety risks including heart attacks and strokes.
- Federal Judge Finds Health Insurer DiscriminatedAgainst Patients with Substance Abuse and Mental Health Disorders - March 25, 2019
- Factors Impacting Maternal Health During Hospital Births - March 22, 2019
- Jury Awards $117 million in Johnson & Johnson’sFirst Trial Loss in Asbestos-Related, Talc Powder Lawsuits - April 24, 2018